What's Happening?
Dr. Keith Roach addresses concerns about Lipoprotein(a) levels in a recent column. A reader, K.P., inquired about her elevated Lp(a) level of 41 mg/dL, which her doctor advised did not require treatment due to the absence of other risk factors. Lp(a) is an
independent risk factor for heart disease, and levels above 180 mg/dL significantly increase the risk of heart attacks and strokes. Currently, there are no specific treatments for Lp(a), although PCSK-9 inhibitors can reduce heart disease risk in individuals with high Lp(a).
Why It's Important?
Understanding the role of Lipoprotein(a) in heart disease is crucial for assessing cardiovascular risk. While elevated Lp(a) levels can indicate increased risk, treatment decisions should consider other risk factors such as LDL cholesterol, blood pressure, and family history. The discussion highlights the need for personalized medicine approaches in managing heart disease risk, potentially influencing clinical guidelines and patient care strategies.
What's Next?
Research into treatments that specifically target Lp(a) is ongoing, with new medications like inclisiran showing promise in reducing Lp(a) and LDL levels. Further studies are needed to confirm their effectiveness in reducing heart attacks and strokes. Healthcare providers may continue to monitor Lp(a) levels as part of a comprehensive risk assessment, adjusting treatment plans based on emerging evidence.
